Trial Profile

International Sentinel Site Surveillance of Patients With Transfusional Hemosiderosis Treated With Deferasirox in Actual Practice Setting

Status: Completed

Phase of Trial: Phase IV

Latest Information Update: 05 Nov 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Deferasirox (Primary)
Indications Haemosiderosis
Focus Adverse reactions; Therapeutic Use
Acronyms SENTINEL study
Sponsors Novartis Pharmaceuticals

Most Recent Events

11 Jan 2017 New trial record
06 Dec 2016 Results assessing safety presented at the 58th Annual Meeting and Exposition of the American Society of Hematology.
06 Dec 2016 Results assessing treatment outcomes presented at the 58th Annual Meeting and Exposition of the American Society of Hematology.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com